Somatostatin Analog

3 Drugs classified under this drug class

Somatostatin Analog. Octreotide 10, 20, 30 mg.
VIALS: 1. (2 vehicle amp + 1 inject set).
By deep intraglut. inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother., or dopamine-agonist tmt.
inapprop. or ineffect., in latency period bef.
radiother. becomes fully effect. Endocrine
gastro-entro-pancreat. (GEP) tumors,
carcinoid tumors.
VIALS: 1. (1 prefilled syringe + 2 needles)
x 20 mg, 30 mg. By deep intraglut.
inject. See lit.
Acromeg. in pts. adequat. controlled on
standard dose Sandostatin S.C. in whom
surg. radiother. inapprop. or ineffect., in
latency period bef. radiother. becomes
fully effect. Endocrine gastro-entropancreat.
(GEP) tumors, carcinoid
tumors.

Somatostatin Analog. Lanreotide (as acetate) 60, 90, 120 mg.
PRE-FILLED SYRINGE: 1. Deep S.C. into
ior ext. quad. of buttock. See Lit.
Acromeg. (when tmt. growth hormone not
normaliz. aft. surg. and/or radiother.),
clinical sympts. carcinoid tumors (aft. test
inject.).
C/I: Hypersens., pregn., lact.

Somatostatin Analog. Lanreotide (as acetate) 30 mg/vial.
VIAL + SOLV (pwdr): 1, 2, 6. Initial: 1
inject. I.M. every 14 days. Insuffic.
response: 1 inject. I.M. every 7-10 days.
Acromeg. (when tmt. growth hormone
not normaliz. aft. surg. and/or
radiother.), clinical sympts. carcinoid
tumors (aft. test inject.). Tmt. prim.
thyrotrophic adenomas responsible for
hypothyroid. as prep. for/complement to
surg. and/or radiother. or where these
ther. unsuitable.
C/I: Hypersens., pregn., lact.